After graduating college I served as a hospice counselor before pursuing a career in research. Working closely with terminally ill patients and their families sparked my interest in understanding the link between nutrition and the prevention of age-related diseases. Since this experience, I have been fortunate to train with experts in the fields of aging, metabolism, and obesity. Current Stern lab research aims to understand the role of glucoregulatory hormone signaling in the pathogenesis of obesity, type II diabetes mellitus, and aging.  More than 25% of the U.S. population greater than 65 years old has Type II diabetes mellitus, representing the highest prevalence of diabetes of any age group. Most research aimed at understanding the consequences of obesity in aging have focused on insulin and downstream signaling cascades, overlooking a potential role for the hormone glucagon. Given that many prominent diabetes treatments target glucagon or glucagon signaling pathways, it is essential to understand the role of glucagon in aging. Our research examines 1) the role of glucagon signaling in obesity-accelerated aging, 3) the role of glucagon signaling in healthspan extension promoted by calorie restriction, and 4) the role of glucagon signaling in exercise mediated improvements in metabolic and physical function. This work will close a significant gap in our understanding of how glucagon alters aging, while allowing us to assess the potential risks associated with inhibition of glucagon signaling.